Parkinson’s disease (PD) is a debilitant neurodegenerative disease that unveils severe physical, and psychological burdens on patients. To date, there is no effective treatment capable of inverting the disease course, freezing the cognitive impairment, and other non-motor features. Solid lipid nanoparticles (SLNs) can represent a promising approach to provide safe and site-specific delivery of naturally occurring compounds counteracting PD symptoms. In this work, SLNs were purposed for the release of a capsaicin-rich extract (CPS-extract) and investigated for their efficacy in PD pathology. SLNs were prepared by using stearic acid (SA) and Brij 78 as lipid and surfactant, respectively. Different formulation parameters, including drug: lipid ratio and surfactant concentrations were investigated. The selected formulation brings together particle sizes of around 200 nm, high encapsulation efficiency (>80 %), and provides 90 % of CPS release within 24 h, which well fits in the Kosermayer-Peppas model. Differential Scanning Calorimetry (DSC) analysis confirmed the presence of the lipid in the solid crys talline state, while stability studies revealed that CPS-extract SLNs preserve their stability for at least 30 days. Moreover, biological assays, performed on retinoic acid/phorbol 12-myristate 13-acetate (RA/PMA) differenti ated SH-SY5Y neuroblastoma cell line, revealed that CPS-extract SLNs possessed a significant protective effect in reducing reactive oxygen species (ROS) increments induced by the neurotoxic agent H2O2.

Solid lipid nanoparticles for efficient delivery of capsaicin-rich extract: Potential neuroprotective effects in Parkinson’s disease

Marinelli, Lisa
Primo
;
Dimmito, Marilisa Pia
Secondo
;
Cacciatore, Ivana;Toto, Eleonora Chiara;Di Rienzo, Annalisa;Palmerio, Ferdinando;Puca, Valentina;Di Filippo, Ester Sara;Fulle, Stefania
Penultimo
;
Di Stefano, Antonio
Ultimo
2024-01-01

Abstract

Parkinson’s disease (PD) is a debilitant neurodegenerative disease that unveils severe physical, and psychological burdens on patients. To date, there is no effective treatment capable of inverting the disease course, freezing the cognitive impairment, and other non-motor features. Solid lipid nanoparticles (SLNs) can represent a promising approach to provide safe and site-specific delivery of naturally occurring compounds counteracting PD symptoms. In this work, SLNs were purposed for the release of a capsaicin-rich extract (CPS-extract) and investigated for their efficacy in PD pathology. SLNs were prepared by using stearic acid (SA) and Brij 78 as lipid and surfactant, respectively. Different formulation parameters, including drug: lipid ratio and surfactant concentrations were investigated. The selected formulation brings together particle sizes of around 200 nm, high encapsulation efficiency (>80 %), and provides 90 % of CPS release within 24 h, which well fits in the Kosermayer-Peppas model. Differential Scanning Calorimetry (DSC) analysis confirmed the presence of the lipid in the solid crys talline state, while stability studies revealed that CPS-extract SLNs preserve their stability for at least 30 days. Moreover, biological assays, performed on retinoic acid/phorbol 12-myristate 13-acetate (RA/PMA) differenti ated SH-SY5Y neuroblastoma cell line, revealed that CPS-extract SLNs possessed a significant protective effect in reducing reactive oxygen species (ROS) increments induced by the neurotoxic agent H2O2.
2024
Inglese
ELETTRONICO
91
10
Article number 105097
Capsaicin, Controlled release, Drug delivery, Parkinson’s disease, Solid lipid nanoparticle
Goal 3: Good health and well-being
https://www.sciencedirect.com/science/article/pii/S1773224723009498
no
10
info:eu-repo/semantics/article
262
Marinelli, Lisa; Dimmito, Marilisa Pia; Cacciatore, Ivana; Toto, Eleonora Chiara; Di Rienzo, Annalisa; Palmerio, Ferdinando; Puca, Valentina; Di Filip...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
open
   Novel Terpenoid-prodrugs with antimicrobial and anti-inflammatory activities for the treatment of severe gastrointestinal diseases
   TAAGID
   Unione europea/MUR
File in questo prodotto:
File Dimensione Formato  
Journal of Drug Delivery Science and Technology 91 (2024) 105097.pdf

accesso aperto

Descrizione: Articolo in rivista
Tipologia: PDF editoriale
Dimensione 3.42 MB
Formato Adobe PDF
3.42 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/836211
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact